Pet industry M&A picks up with new winter deals
Pet industry M&A is showing fresh momentum after a relatively restrained stretch, with winter deals cutting across nutrition, distribution, and digital services. The pattern is less about splashy volume than about targeted expansion: buyers are using acquisitions to add premium brands, enter new geographies, and tighten control over supply chains and customer relationships. Recent moves include AlphaPet Ventures’ acquisition of Belgium’s Cpro Food, the planned merger of Covetrus and MWI Animal Health, and Rover’s continued expansion after Blackstone took the company private. (webdisclosure.com)
That matters because the pet sector’s M&A story has changed since the pandemic boom. GlobalPETS reported that the first half of 2025 saw a 9% drop in overall deal volume but a 15% increase in deal value, suggesting buyers became more selective even as they were still willing to pay for assets with scale or strategic value. The same reporting said North America accounted for 17% of analyzed pet investments, while activity also extended into wellness, veterinary, pharma, accessories, and tech. In other words, consolidation hasn’t disappeared, it’s matured. (globalpetindustry.com)
The winter wave includes several distinct playbooks. AlphaPet said on March 27, 2026 that it had added Cpro Food, a Belgian super-premium dog and cat food brand, marking its fifth acquisition since 2020 as it builds a Europe-wide portfolio of local premium labels. In services, Rover’s international strategy has accelerated since Blackstone’s $2.3 billion acquisition closed on February 27, 2024; Rover then moved to buy Australia’s Mad Paws in July 2025, with both companies framing the deal as a way to deepen Rover’s reach beyond North America and Europe while keeping the Mad Paws brand in market. (webdisclosure.com)
The most consequential deal for veterinary professionals may be the planned combination of Covetrus and MWI Animal Health. In the March 2026 announcement, Cencora described Covetrus as a global animal health technology and services company with more than 5,000 employees and more than 100,000 customers worldwide, serving companion, equine, and large-animal markets. The companies said the transaction is intended to create a broader platform for animal health products and services, but they also noted the deal still requires regulatory approvals and is not expected to close before the end of Cencora’s fiscal year on September 30, 2026. (s203.q4cdn.com)
Industry observers are reading these deals as a sign that buyers still believe the category has long-term upside, even in a tougher operating environment. GlobalPETS noted that recent acquisitions have been driven by geographic expansion, specialization, and future positioning, and cited expectations that a handful of larger processes in late 2025 and early 2026 could help define the next cycle. Separate market commentary from Lincoln International, cited by PETS International, said European pet consumables had been running at roughly 70 to 80 transactions annually over the prior three years, with consolidation increasingly shaped by market share goals, synergies, quality, sustainability, and digital transformation. (globalpetindustry.com)
Why it matters: Veterinary teams should pay attention because these deals can reshape the infrastructure around care, not just consumer-facing brands. When distribution consolidates, clinics may eventually feel it in pricing leverage, product availability, software integration, delivery models, and manufacturer access. When digital service platforms expand, they can influence how pet parents discover care options, compare convenience, and split spending across retail, telehealth, pharmacy, and in-person veterinary channels. And when premium nutrition companies consolidate, they often gain broader marketing and distribution muscle, which can affect the diets pet parents ask about in exam rooms. These are business moves, but they can have clinical and operational ripple effects. (s203.q4cdn.com)
What to watch: The next signals will be whether regulators allow the Covetrus-MWI transaction to proceed on the expected timeline, whether more buyers pursue cross-border acquisitions in premium nutrition and pet services, and whether the larger deals now in the pipeline actually close. If they do, 2026 could look less like a rebound in deal count and more like a year when a smaller number of strategically important transactions redraw parts of the veterinary and pet care landscape. (s203.q4cdn.com)